ERK1/2 — LLMpedia

ERK1/2
Name	Extracellular signal-regulated kinases 1 and 2
Uniprot	P27361; P28482
Organism	Homo sapiens
Length	379; 360
Catalytic activity	serine/threonine kinase

Contents

ERK1/2

Introduction

ERK1/2 are mitogen-activated protein kinases that occupy central positions within signaling cascades triggered by growth factors, stressors, and receptors. ERK1/2 transduce signals from membrane-associated complexes to nuclear effectors, modulating transcriptional programs and cytoskeletal dynamics in contexts studied by researchers from Max Planck Society to National Institutes of Health laboratories. Investigators affiliated with institutions such as Harvard University, Stanford University, Massachusetts Institute of Technology, University of Cambridge, and University of Tokyo have characterized ERK1/2 in models ranging from Saccharomyces cerevisiae studies at Cold Spring Harbor Laboratory to mammalian work at Johns Hopkins University.

ERK1 and ERK2 are distinct gene products encoded by MAPK3 and MAPK1, respectively, and have been compared in structural studies from groups at European Molecular Biology Laboratory, Swiss Federal Institute of Technology Zurich, and the Riken Institute. High-resolution crystallography performed by teams at Brookhaven National Laboratory and Imperial College London revealed a bilobed kinase domain with activation loop phosphorylation sites; these data complement mutational analyses from University of California, San Francisco and Yale University. Comparative genomics efforts involving Broad Institute, Wellcome Trust Sanger Institute, and National Center for Biotechnology Information identify conserved motifs across vertebrate species studied by researchers at University of Oxford and University of Melbourne. Isoform-specific functions were dissected in knockout models generated by consortia associated with European Research Council and Howard Hughes Medical Institute.

ERK1/2 activation is classically initiated by receptor tyrosine kinases such as Epidermal growth factor receptor and Platelet-derived growth factor receptor, which engage adaptors characterized in studies at Cold Spring Harbor Laboratory and University of Chicago. Activated Ras family members, including work on HRAS and KRAS from Dana-Farber Cancer Institute, recruit RAF kinases studied at Memorial Sloan Kettering Cancer Center; RAF phosphorylates MEK1/2 characterized at Cancer Research UK centers, which in turn dually phosphorylate ERK1/2. This cascade has been mapped in signaling atlases maintained by European Bioinformatics Institute, GENCODE, and The Jackson Laboratory, and pharmacological modulation has been assessed in clinical trials coordinated by Food and Drug Administration and European Medicines Agency.

ERK1/2 regulate proliferation paradigms examined in cancer centers such as MD Anderson Cancer Center and Mayo Clinic, differentiation programs probed by labs at Stanford University School of Medicine and University College London, and synaptic plasticity studied by researchers at Columbia University and University of California, Los Angeles. Roles in cell migration, apoptosis resistance, and metabolism were investigated by teams at Salk Institute, Fred Hutchinson Cancer Center, and University of Pennsylvania. Developmental biology contributions from Max Planck Institute for Developmental Biology and European Molecular Biology Organization laboratories link ERK signaling to organogenesis models used at University of Copenhagen and Karolinska Institutet.

Regulatory mechanisms include dual phosphorylation and dephosphorylation by phosphatases characterized by groups at Institute Pasteur and Cold Spring Harbor Laboratory. Interaction partners identified via proteomics at Proteomics Resource Center, European Proteomics Association, and National Institute of Standards and Technology include scaffold proteins studied at Weizmann Institute of Science and transcription factors analyzed at University of California, Berkeley. ERK1/2 engagement with cyclins and CDKs has been detailed by investigators at Rockefeller University and Johns Hopkins Bloomberg School of Public Health, while cross-talk with PI3K/AKT pathways was elucidated in collaborations involving UC San Diego and University of Michigan. Ubiquitination and SUMOylation regulation were reported by labs at Princeton University and Cornell University.

Aberrant ERK1/2 signaling is implicated in oncogenesis documented in case series from Memorial Sloan Kettering Cancer Center, therapeutic resistance characterized at Dana-Farber Cancer Institute, and targeted treatment trials run by National Cancer Institute cooperative groups. Neurodegenerative disease associations have been explored by researchers at National Institute on Aging and Alzheimer's Association–funded teams, while cardiovascular implications were studied at Cleveland Clinic and Mount Sinai Health System. Pathways involving ERK1/2 are targeted by small molecules developed by companies like Novartis, Pfizer, Roche, and tested in multicenter trials coordinated by World Health Organization-affiliated networks. Genetic syndromes with MAPK pathway mutations have been cataloged by clinical genetics units at Mayo Clinic and Great Ormond Street Hospital.

Common experimental approaches include in vitro kinase assays standardized by American Society for Biochemistry and Molecular Biology, phospho-specific antibodies produced by commercial providers and validated in repositories like Addgene, and live-cell imaging platforms developed at Janelia Research Campus and European Molecular Biology Laboratory. Genetic manipulation via CRISPR-Cas9 protocols refined at Broad Institute and viral delivery systems employed by Salk Institute laboratories enable isoform-specific studies. Databases and resources such as UniProt, Protein Data Bank, Gene Ontology Consortium, and curated datasets from ArrayExpress and Gene Expression Omnibus support reproducible ERK1/2 research.